Literature DB >> 20861914

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.

T Zenz1, D Vollmer, M Trbusek, J Smardova, A Benner, T Soussi, H Helfrich, M Heuberger, P Hoth, M Fuge, T Denzel, S Häbe, J Malcikova, P Kuglik, S Truong, N Patten, L Wu, D Oscier, R Ibbotson, A Gardiner, I Tracy, K Lin, A Pettitt, S Pospisilova, J Mayer, M Hallek, H Döhner, S Stilgenbauer.   

Abstract

The TP53 mutation profile in chronic lymphocytic leukemia (CLL) and the correlation of TP53 mutations with allele status or associated molecular genetics are currently unknown. We performed a large mutation analysis of TP53 at four centers and characterized the pattern of TP53 mutations in CLL. We report on 268 mutations in 254 patients with CLL. Missense mutations appeared in 74% of cases compared with deletions and insertions (20%), nonsense (4%) and splice site (2%) mutations. The majority (243 of 268) of mutations were located in the DNA-binding domain. Transitions were found in 131 of 268 mutations, with only 41 occurring at methylated CpG sites (15%), suggesting that transitions at CpGs are uncommon. The codons most frequently mutated were at positions 175, 179, 248 and 273; in addition, we detected a common 2-nt deletion in the codon 209. Most mutations (199 of 259) were accompanied by deletion of the other allele (17p-). Interestingly, trisomy 12 (without 17p-) was only found in one of 60 cases with TP53 mutation (without 17p-) compared with 60 of 16 in the cohort without mutation (P=0.006). The mutational profile was not different in the cohorts with and without previous therapy, suggesting that the mechanism underlying the development of mutations may be similar, independent of treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20861914     DOI: 10.1038/leu.2010.208

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  42 in total

1.  Tailoring of chronic lymphatic leukemia therapy.

Authors:  Ashraf M Elhefni
Journal:  Am J Blood Res       Date:  2013-08-19

2.  Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia.

Authors:  L Mansouri; L-A Sutton; V Ljungström; E F Sörqvist; R Gunnarsson; K E Smedby; G Juliusson; K Stamatopoulos; M Nilsson; R Rosenquist
Journal:  Leukemia       Date:  2013-10-31       Impact factor: 11.528

3.  On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.

Authors:  D Cortese; L-A Sutton; N Cahill; K E Smedby; C Geisler; R Gunnarsson; G Juliusson; L Mansouri; R Rosenquist
Journal:  Leukemia       Date:  2013-11-12       Impact factor: 11.528

4.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Hossein Khiabanian; Valeria Spina; Carmela Ciardullo; Alessio Bruscaggin; Rosella Famà; Silvia Rasi; Sara Monti; Clara Deambrogi; Lorenzo De Paoli; Jiguang Wang; Valter Gattei; Anna Guarini; Robin Foà; Raul Rabadan; Gianluca Gaidano
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

Review 5.  Evolving understanding of the CLL genome.

Authors:  Michaela Gruber; Catherine J Wu
Journal:  Semin Hematol       Date:  2014-05-15       Impact factor: 3.851

6.  CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Authors:  M Dal Bo; P Bulian; R Bomben; A Zucchetto; F M Rossi; F Pozzo; E Tissino; D Benedetti; T Bittolo; P Nanni; I Cattarossi; E Zaina; H Chivilò; M Degan; F Zaja; G Pozzato; A Chiarenza; F Di Raimondo; M I Del Principe; G Del Poeta; D Rossi; G Gaidano; V Gattei
Journal:  Leukemia       Date:  2016-04-25       Impact factor: 11.528

7.  TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.

Authors:  Barbara Kantorova; Jitka Malcikova; Jana Smardova; Sarka Pavlova; Martin Trbusek; Nikola Tom; Karla Plevova; Boris Tichy; Sim Truong; Eva Diviskova; Jana Kotaskova; Alexandra Oltova; Nancy Patten; Yvona Brychtova; Michael Doubek; Jiri Mayer; Sarka Pospisilova
Journal:  Tumour Biol       Date:  2014-12-20

Review 8.  High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.

Authors:  Edward Nabrinsky; Alexey V Danilov; Paul B Koller
Journal:  Curr Hematol Malig Rep       Date:  2021-01-28       Impact factor: 3.952

Review 9.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

Review 10.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.